Program
rozanolixizumab
Also written as “Rozanolixizumab”, “UCB7665” and “UCB7665 Intravenous 1”.
Its studies are mostly in Myasthenia Gravis · Purpura, Thrombocytopenic, Idiopathic · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease · Fibromyalgia, led by UCB.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| UCB | 235 open or running | phase 4since Nov 17, 2025 | Aug 18, 2014 | May 6, 2027phase 3 · NCT05063162 |
Also a collaborator on its studies: parexel.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 10 studies since Aug 18, 2014.
- Oct 15, 2020Phase 3 study in Purpura, Thrombocytopenic, IdiopathicNCT04596995 · 43 enrolled · United States, China, Georgia and more
- Nov 5, 2020Phase 3 study in Myasthenia GravisNCT04650854 · 165 enrolled · United States, Canada, Czechia and more
- Mar 30, 2021Phase 1 study in Healthy Study ParticipantsNCT04828343 · 32 enrolled · United Kingdom
- May 3, 2021Phase 2 study in Leucine-Rich Glioma Inactivated 1 Autoimmune EncephalitisNCT04875975 · 12 enrolled · United States, Australia, Belgium and more
- Sep 21, 2021Phase 3 study in Myelin Oligodendrocyte Glycoprotein Antibody-Associated DiseaseNCT05063162 · 113 enrolled · United States, Australia, Belgium and more
- Nov 30, 2022Phase 2 study in FibromyalgiaNCT05643794 · 63 enrolled · United Kingdom
- Jan 4, 2023Phase 3 study in Myasthenia GravisNCT05681715 · 62 enrolled · United States, Canada, Georgia and more
- Sep 25, 2023Phase 3 study in Myasthenia GravisNCT06149559 · 14 enrolled · Italy, Japan, Poland and more
- Jul 22, 2024Phase 3 study in Myasthenia GravisNCT06540144 · 13 enrolled · Italy, Japan, Poland and more
- Dec 2, 2024Phase 1 study in Healthy ParticipantsNCT06720714 · 15 enrolled · United States
- Nov 17, 2025Phase 4 study in Myasthenia GravisNCT07246564 · 40 enrolled · China
- Mar 5, 20262 phase 3 studies in Myasthenia GravisNCT07463521, NCT07465289
- Oct 16, 2026Primary completion moved from 2027-08-17 to 2027-10-05Date moved laterphase 3 · +2 months · NCT06540144
- Oct 27, 2026Primary completion moved from 2031-01-23 to 2031-03-17Date moved laterphase 3 · +2 months · NCT07465289
Ahead
- May 6, 2027Primary completion: phase 3 study in Myelin Oligodendrocyte Glycoprotein Antibody-Associated DiseaseNCT05063162
- Oct 5, 2027Primary completion: phase 3 study in Myasthenia GravisNCT06540144
- Oct 15, 2027Primary completion: phase 4 study in Myasthenia GravisNCT07246564
- Dec 1, 2028Primary completion: phase 3 study in Myasthenia GravisNCT07463521
TargetBeta
“IgG receptor FcRn large subunit p51 inhibitor”ChEMBL 37, by rule
Other programs on FCGRT
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| efgartigimod alfarule | argenx | phase 4 | 48 |
| nipocalimabrule | Johnson & Johnson | phase 3 | 24 |
| batoclimabrule | immunovant-sciences-gmbh | phase 3 | 18 |
Studies
All 23 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07465289Myasthenia Gravis · United States, China, France and more | 3 | Recruiting | Mar 17, 2031 | 100 |
| NCT07463521Myasthenia Gravis · United States, Canada, China and more | 3 | Recruiting | Dec 1, 2028 | 120 |
| NCT07246564Myasthenia Gravis · China | 4 | Active, not recruiting | Oct 15, 2027 | 40 |
| NCT06720714Healthy Participants · United States | 1 | Completed | May 12, 2025 | 15 |
| NCT06540144Myasthenia Gravis · Italy, Japan, Poland and more | 3 | Active, not recruiting | Oct 5, 2027 | 13 |
| NCT06149559Myasthenia Gravis · Italy, Japan, Poland and more | 3 | Completed | Oct 5, 2026 | 14 |
| NCT05681715Myasthenia Gravis · United States, Canada, Georgia and more | 3 | Completed | Apr 23, 2024 | 62 |
| NCT05643794Fibromyalgia · United Kingdom | 2 | Completed | May 28, 2024 | 63 |
| NCT05063162Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease · United States, Australia, Belgium and more | 3 | Active, not recruiting | May 6, 2027 | 113 |
| NCT04875975Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis · United States, Australia, Belgium and more | 2 | Terminated | Mar 8, 2024 | 12 |
| NCT04828343Healthy Study Participants · United Kingdom | 1 | Completed | Apr 11, 2022 | 32 |
| NCT04650854Myasthenia Gravis · United States, Canada, Czechia and more | 3 | Completed | Jan 25, 2024 | 165 |
| NCT04596995Purpura, Thrombocytopenic, Idiopathic · United States, China, Georgia and more | 3 | Terminated | Dec 21, 2022 | 43 |
| NCT04224688Purpura, Thrombocytopenic, Idiopathic · United States, Bulgaria, China and more | 3 | Terminated | Apr 25, 2022 | 30 |
| NCT04200456Purpura, Thrombocytopenic, Idiopathic · United States, Bulgaria, France and more | 3 | Terminated | Mar 21, 2022 | 33 |
| NCT04124965Myasthenia Gravis · United States, Canada, Czechia and more | 3 | Completed | Sep 1, 2021 | 71 |
| NCT04051944Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Belgium, Denmark and more | 2 | Completed | Nov 10, 2021 | 21 |
| NCT03971422Myasthenia Gravis · United States, Belgium, Canada and more | 3 | Completed | Aug 31, 2021 | 200 |
| NCT03861481Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Belgium, Denmark and more | 2 | Completed | Mar 31, 2021 | 34 |
| NCT03859219Healthy-volunteers · United Kingdom | 1 | Completed | Apr 28, 2020 | 65 |
| NCT03052751Myasthenia Gravis · United States, Belgium, Canada and more | 2 | Completed | May 31, 2018 | 43 |
| NCT02718716Thrombocytopenia · Australia, Bulgaria, Czechia and more | 2 | Completed | Feb 4, 2019 | 66 |
| NCT02220153Healthy · United Kingdom | 1 | Completed | Sep 2015 | 41 |
How it is read
Names in the registry
- “Rozanolixizumab”, 16 entries
- “rozanolixizumab”, 4 entries
- “UCB7665”, 2 entries
- “UCB7665 Intravenous 1”, 1 entry
- “UCB7665 Intravenous 2”, 1 entry
Conditions, from the studies’ own filings
- Myasthenia Gravis, 10 studies
- Purpura, Thrombocytopenic, Idiopathic, 3 studies
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, 2 studies
- Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease, 1 study
- Fibromyalgia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.